Download PDF
Dtsch Med Wochenschr 2004; 129(18): 1027-1031
DOI: 10.1055/s-2004-824835
Übersichten
Gastroenterologie / Pharmakologie
© Georg Thieme Verlag Stuttgart · New York

Gastrointestinale Nebenwirkungen von Medikamenten[1]

Gastrointestinal side effects of drugsD. Jaspersen1 , K.-U Petersen2
  • 1Medizinische Klinik II, Klinikum Fulda gAG
  • 2Institut für Pharmakologie und Toxikologie, RWTH Aachen
Further Information

Publication History

eingereicht: 27.8.2003

akzeptiert: 15.1.2004

Publication Date:
20 July 2004 (online)

Also available at
    Permissions and Reprints

Unerwünschte Arzneimittelwirkungen (UAW) können im gesamten Verdauungstrakt auftreten. Wichtige Beispiele im oberen Intestinaltrakt sind Schleimhautschäden durch Bisphosphonate und nichtsteroidale Antirheumatika (NSAR); die letztgenannten schädigen nicht selten auch Dünn- und Dickdarm. Häufige Nebenwirkung einer antibiotischen Behandlung ist die Enterokolitis; zahlreiche Pharmaka wie Diuretika können Ursache einer akuten Pankreatitis sein. In diesem Beitrag sollen die wesentlichen UAW im Gastrointestinaltrakt und ihre Therapie diskutiert werden.

1 Herrn Prof. Dr. J. F. Riemann gewidmet

Literatur

  • 1 Ablin D S, Ziegler M. Ulcerative type of colitis associated with the use of high strength pancreatic enzyme supplements in cystic fibrosis.  Pediatr Radiol. 1995;  25 113-115
    Google Scholar
  • 2 Allen M, Mellow M, Robinson M G, Orr W C. Comparison of calcium channel blocking agents and an anticholinergic agent on oesophageal function.  Aliment Pharmacol Ther. 1987;  1 153-159
    Google Scholar
  • 3 Allison M C, Howatson A G, Torrance C J. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs.  N Engl J Med. 1992;  327 749-754
    Google Scholar
  • 4 Andersen V, Sonne J, Andersen M. Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999.  Eur J Clin Pharmacol. 2001;  57 517-521
    Google Scholar
  • 5 Arzneimittelkommission der Deutschen Ärzteschaft . Zur Sicherheit von COX-2-Inhibitoren.  Dtsch Ärztebl. 2002;  99 1291-1292
    Google Scholar
  • 6 Ballinger A B, Smith G. COX-2 vs NSAIDs: gastrointestinal damage and prevention.  Exp Opin Pharmacother. 2001;  2 31-40
    Google Scholar
  • 7 Bansi D S, Price A, Russell C, Sarner M. Fibrosing colonopathy in an adult owing to overuse of pancreatic enzyme supplements.  Gut. 2000;  46 283-285
    Google Scholar
  • 8 Bombardier C, Laine L, Reicin A. et al. VIGOR study group . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.  N Engl J Med. 2000;  343 1520-1528
    Google Scholar
  • 9 Boyce H W. Drug-induced esophageal damage: diseases of medical progress.  Gastrointest Endosc. 1998;  47 547-550
    Google Scholar
  • 10 Byrne M F, McGuiness J, Smyth C M. et al . Nonsteroidal anti-inflammatory drug-induced diaphragms and ulceration in the colon.  Eur J Gastroenterol Hepatol. 2002;  14 1265-1269
    Google Scholar
  • 11 Chan F KL, Chung S CS, Suen R N. et al . Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.  N Engl J Med. 2001;  344 967-973
    Google Scholar
  • 12 Chocarro Martinez A, Galindo Tobal F, Ruiz-Irastorza G. et al . Risk factors for esophageal candidiasis.  Eur J Clin Microbiol Infect Dis. 2000;  19 96-100
    Google Scholar
  • 13 De Abajo F J, Garcia Rodriguez L A, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population-based case-control study.  Br Med J. 1999;  319 1106-1109
    Google Scholar
  • 14 El-Serag H B, Sonnenberg A. Association of esophagitis and esophageal strictures with diseases treated with non-steroidal anti-inflammatory drugs.  Am J Gastroenterol. 1997;  92 52-56
    Google Scholar
  • 15 De Groen P C, Lubbe D F, Laurence C B. Esophagitis associated with the use of alendronate.  N Engl J Med. 1996;  335 1016-1021
    Google Scholar
  • 16 Garcia Rodriguez L A, Hernandez-Diaz S, De Abajo F J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies.  Br J Clin Pharmacol. 2001;  52 563-571
    Google Scholar
  • 17 Garcia Rodriguez L A, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs.  Epidemiology. 2001;  12 570-576
    Google Scholar
  • 18 Hawkey C J, Langman M JS. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.  Gut. 2003;  52 600-608
    Google Scholar
  • 19 Ishikawa H, Iwakiri K, Sugiura T, Kobayashi M. Effect of nifedipine administration (10 mg) on esophageal acid exposure.  J Gastroenterol. 2000;  35 43-46
    Google Scholar
  • 20 Jaspersen D. Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management.  Drug Saf. 2000;  22 237-249
    Google Scholar
  • 21 Jaspersen D. Extragastrale Nebenwirkungen nicht steroidaler Antirheumatika.  Dtsch Med Wochenschr. 1998;  132 669-673
    Google Scholar
  • 22 Kikendall J W, Mellow M H. Effect of sublingual nitroglycerin and long-acting nitrate preparations on esophageal motility.  Gastroenterology. 1980;  79 703-706
    Google Scholar
  • 23 Kikendall J W. Pill esophagitis.  J Clin Gastroenterol. 1999;  28 298-305
    Google Scholar
  • 24 Langman M J, Weil J, Wainwright G HT P. et al . Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs.  Lancet. 1994;  343 1075-1078
    Google Scholar
  • 25 Lankisch P G, Droege M, Gottesleben F. Drug-induced acute pancreatitis: incidence and severity.  Gut. 1995;  37 565-567
    Google Scholar
  • 26 Larkai E N, Smith J L, Lidsky M D, Graham D Y. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use.  Am J Gastroenterol. 1987;  82 1153-1158
    Google Scholar
  • 27 Lewis S C, Langman M J, Laporte J R, Matthews J N, Rawlins M D, Wiholm B E. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data.  Br J Clin Pharmacol. 2002;  54 320-326
    Google Scholar
  • 28 Limmer S, Ittel T H, Wietholz H. Sekundär- und Primärprophylaxe der ASS-/NSAR-Gastropathie: Eine Übersicht anhand vier klinischer Szenarien.  Z Gastroenterol. 2003;  41 719-728
    Google Scholar
  • 29 Lloyd-Still J D. Cystic fibrosis and colonic strictures: a new ‘iatrogenic’ disease.  J Clin Gastroenterol. 1995;  21 2-5
    Google Scholar
  • 30 Mallory A, Kern F. Drug-induced pancreatitis: a critical review.  Gastroenterology. 1980;  78 813-820
    Google Scholar
  • 31 Makins R, Ballinger A. Gastrointestinal side effects of drugs. Expert Opin.  Drug Saf. 2003;  2 421-429
    Google Scholar
  • 32 McArthur K E. Drug-induced pancreatitis.  Aliment Pharmacol Ther. 1996;  10 23-27
    Google Scholar
  • 33 Milminick T, Frick T W. Drug-induced pancreatitis.  Drug Saf. 1996;  14 406-409
    Google Scholar
  • 34 Nassar N N, Gregg C R. Oesophageal infections.  Curr Treat Options Gastroenterol. 1998;  1 56-63
    Google Scholar
  • 35 Pemberton J. Oesophageal obstruction and ulceration caused by oral potassium therapy.  Br Heart J. 1970;  32 267-268
    Google Scholar
  • 36 Petersen K U, Jaspersen D. Medication-induced esophageal disorders. Expert Opin.  Drug Saf. 2003;  5 1-13
    Google Scholar
  • 37 Ratnaike R N, Jones T E. Mechanisms of drug-induced diarrhoea in the elderly.  Drugs Aging. 1998;  13 245-253
    Google Scholar
  • 38 Rünzi M, Layer P. Drug-associated pancreatitis: facts and fiction.  Pancreas. 1996;  13 100-109
    Google Scholar
  • 39 Simon L S, Weaver A L, Graham D Y. et al . Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.  JAMA. 1999;  282 1921-1928
    Google Scholar
  • 40 Silverstein F E, Faich G, Goldstein. et al . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.  JAMA. 2000;  284 1247-1255
    Google Scholar
  • 41 Smale S, Tibble J, Sigthorsson G, Bjarnason I. Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine.  Best Pract Res Clin Gastroenterol. 2001;  15 723-738
    Google Scholar
  • 42 Smyth R L, van Velzen D, Smyth R A. et al . Strictures of the ascending colon in cystic fibrosis and high-strength pancreatic enzyme supplements.  Lancet. 1994;  343 85-86
    Google Scholar
  • 43 Stein J, Schröder O. Antibiotikaassoziierte Kolitis - Eine relevante Krankheit?. Urban und Schwarzenberg, München In: Klinik der Gegenwart, Gerock W, Schöllermich J (HRSG) 1997: 1-26
    Google Scholar
  • 44 Thumshirn M, Fried M. Prophylaxe und Therapie NSAR-induzierter Ulzera: ein Update.  Dtsch med Wochenschr. 2000;  125 975-978
    Google Scholar
  • 45 Vanek V W, Al-Salti M. Acute pseudo-obstruction of the colon (Ogilvie’s syndrome). An analysis of 400 cases.  Dis Colon Rectum. 1986;  29 203-210
    Google Scholar
  • 46 Van Velzen D, Ball L M, Dezfulian A R, Southgate A, Howard C V. Comparative and experimental pathology of fibrosing colonopathy.  Postgrad Med J. 1996;  72 S39-S48
    Google Scholar
  • 47 Wolfe M M, Lichtenstein D R, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs.  N Engl J Med. 1999;  340 1888-1899
    Google Scholar
  • 48 Wright J M. The double-edged sword of COX-2 selective NSAIDs.  Can Med Assoc J. 2002;  167 1131-1137
    Google Scholar

1 Herrn Prof. Dr. J. F. Riemann gewidmet

Prof. Dr. Daniel Jaspersen

Klinikum Fulda gAG, Med. Klinik II

Pacelliallee 4

36043 Fulda

Email: d.jaspersen.medII@klinikum-fulda.de

      >